Analyst firms · Susquehanna · AFRM

Susquehanna AFRM price target and rating history

Affirm Holdings Inc. (AFRM) · Finance

Susquehanna rates Affirm Holdings Inc. (AFRM) Positive with a $65 price target, as of its latest action on May 9, 2025. It has published 3 rating actions on AFRM since September 2024, including 1 upgrade and 1 downgrade. Across 12 firms with a AFRM price target in the last 12 months, the median target is $93.50.

Current rating
Positive
Price target
$65
Median target, all firms
$93.50
Actions on AFRM
3

Susquehanna price target on AFRM

$65$59$5220252026
Susquehanna price target on AFRM, each point a stated target, September 2024 to May 2025.

Every Susquehanna rating on AFRM

How other firms rate AFRM

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Monness, Crespi, HardtBuy$90Oct 26, 2026
Wolfe ResearchOutperform$90Sep 14, 2026
Loop CapitalBuy$105Sep 9, 2026
ScotiabankSector OutperformSep 2, 2026
OppenheimerOutperform$104Aug 28, 2026
BernsteinOutperform$100Jul 22, 2026
BarclaysOverweight$97Jul 8, 2026
Piper SandlerOverweight$103Jun 30, 2026
Morgan StanleyEqual-Weight$79Jun 25, 2026
BMO Capital MarketsOutperform$75Apr 22, 2026
BofA SecuritiesBuy$82Mar 5, 2026
Robert W. BairdNeutral$55Feb 20, 2026
NeedhamBuy$100Jan 27, 2026

Questions about Susquehanna and AFRM

What is Susquehanna's price target for AFRM?
Susquehanna's latest stated price target for Affirm Holdings Inc. (AFRM) is $65, from its action on May 9, 2025.
What is Susquehanna's rating on AFRM?
Susquehanna rates AFRM Positive, a bullish rating, as of May 9, 2025.
When did Susquehanna last change its view on AFRM?
On May 9, 2025, Susquehanna upgrades to Positive from Neutral, price target $65.
How does Susquehanna's AFRM target compare with other analysts?
Across 12 firms with a AFRM price target in the last 12 months, the median target is $93.50.

More AFRM rating histories

All Susquehanna ratingsAFRM news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.